Contribute Try STAT+ Today

Several advocacy groups have filed a complaint with antitrust authorities in Brazil, alleging Gilead charged “abusive” prices for a hepatitis C treatment and asked the government to fine the company, in addition to issuing a compulsory license so that lower-cost versions can be made available.

In their filing, the groups argue that “unlawful conduct” carried out by Gilead “clearly affects the public interest,” because the prices charged by the drug maker led the government to ration the Sovaldi medication. This purportedly contributed to nearly 6,000 deaths from the disease between 2015 and 2017, according to documents filed with the Administrative Council for Economic Defense, or CADE (in English and Portuguese).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.